Glioblastoma has claimed the lives of U.S. senators, celebrated musicians, star athletes, and everyday people whose stories never made the news. John McCain, Ted Kennedy, Beau Biden, and Brittany Maynard are among the most widely recognized names, but the list stretches across professions and decades. What unites these cases is the disease’s stubbornness: even with access to top medical institutions and experimental treatments, glioblastoma carries a median survival of roughly six to ten months, and most patients die within two years of diagnosis.1PubMed Central. Trends in Treatment and Survival Among Patients with Glioblastoma in the United States from 2000 to 2020 The prominence of these individuals brought unprecedented attention to a cancer that had long been underfunded relative to its lethality.
Politicians and Public Servants
No single category of public life has been hit harder, in terms of public awareness, than American politics. Senator John McCain of Arizona was diagnosed with glioblastoma in July 2017 at the age of 80. Despite undergoing surgery, radiation, and chemotherapy at the Mayo Clinic in Phoenix, he died just over a year later in August 2018. His case drew enormous national attention and directly influenced advocacy: the U.S. Senate unanimously passed a bipartisan resolution designating July 17, 2019, as the inaugural Glioblastoma Awareness Day.2Ivy Blog. In Arizona, The Fight Against Brain Cancer is Personal
Senator Edward “Ted” Kennedy’s diagnosis came in May 2008, after he suffered a seizure at his home on Cape Cod. He was 76 and one of the longest-serving members of the U.S. Senate. Kennedy underwent surgery at Duke University Medical Center followed by radiation and temozolomide, the standard chemotherapy agent for the disease. He returned to the Senate floor for a key Medicare vote just months after his craniotomy, a moment that drew a standing ovation. He died in August 2009, roughly fifteen months after diagnosis.
Beau Biden, the eldest son of then-Vice President Joe Biden, was diagnosed with glioblastoma in 2013 at the age of 44. A former Attorney General of Delaware and an Iraq War veteran, Beau Biden initially responded to treatment and was declared to be in remission, but the cancer returned. He died in May 2015 at Walter Reed National Military Medical Center. His death was a driving force behind the Cancer Moonshot initiative launched during the Obama administration, which aimed to accelerate cancer research across all types. Among political operatives, Lee Atwater, the hard-charging Republican strategist who managed George H.W. Bush’s 1988 presidential campaign, was diagnosed with a malignant brain tumor in 1990 at just 39 years old. He died in March 1991. His case was among the earlier high-profile glioblastoma deaths to receive sustained media coverage.
Musicians, Athletes, and Public Advocates
Gordon Downie, the lead singer of the Canadian rock band The Tragically Hip, was diagnosed with glioblastoma in December 2015. His response became one of the most emotionally charged moments in Canadian cultural life: in the summer of 2016, the band embarked on a farewell tour, with the final concert in Kingston, Ontario, broadcast live by the CBC and watched by roughly a third of the Canadian population. Downie continued working on music and advocacy for Indigenous reconciliation throughout his treatment. He died in October 2017 at the age of 53.
In American sports, pitcher Tug McGraw of the Philadelphia Phillies and New York Mets was diagnosed with glioblastoma in 2003. He had surgery to remove the tumor and underwent treatment, but the cancer progressed. He died in January 2004 at the age of 59. His son, country music star Tim McGraw, has since been involved in brain cancer awareness efforts.
Brittany Maynard’s story reached a different kind of prominence. Diagnosed with glioblastoma in 2014 at the age of 29, she chose to move from California to Oregon in order to access that state’s Death with Dignity Act, which allows terminally ill patients to end their own lives with prescribed medication. She became the public face of the right-to-die movement in the United States, recording videos that went viral and lobbying for similar legislation in other states. She died on November 1, 2014, on her own terms. Her advocacy is widely credited with influencing the passage of California’s End of Life Option Act the following year.
Going further back, the composer George Gershwin died of a brain tumor in 1937 at the age of 38. While the modern classification of glioblastoma did not yet exist, retrospective analysis of his case strongly suggests the tumor was consistent with what we now call glioblastoma. His death was startlingly rapid; he went from experiencing headaches and coordination problems to dying on an operating table in a matter of weeks.
Why Wealth and Access Rarely Change the Outcome
One of the most striking and unsettling lessons from these high-profile cases is how little advantage money and connections seem to buy against glioblastoma. McCain had the Mayo Clinic. Kennedy had Duke and Massachusetts General. Beau Biden had the full resources of the National Institutes of Health and Walter Reed. None survived longer than about fifteen months. These timelines are consistent with what population-level data show: even with the most aggressive combination of surgery, radiation, and chemotherapy, the average survival hovers around a year.
A multicenter study found a mean survival time of about thirteen months for the overall patient population, with the one-year survival rate sitting at roughly 45 percent.3PubMed Central. Impact of Age and Gender on Survival of Glioblastoma Multiforme Patients: A Multicenter Retrospective Study National data from the United States show that median overall survival improved from about six months in 2000 to about ten months by 2020, largely thanks to the adoption of multimodal therapy combining surgery with radiation and temozolomide.1PubMed Central. Trends in Treatment and Survival Among Patients with Glioblastoma in the United States from 2000 to 2020 That shift is meaningful in percentage terms, but the raw numbers remain grim.
Age is one of the strongest predictors of how long someone lives after diagnosis. Patients under 60 have a one-year survival rate around 75 percent, compared to roughly 35 percent for those over 60. Women also appear to fare somewhat better, with a one-year survival rate of about 60 percent compared to 40 percent for men, and a mean survival about five months longer.3PubMed Central. Impact of Age and Gender on Survival of Glioblastoma Multiforme Patients: A Multicenter Retrospective Study Beau Biden’s relative youth at diagnosis (44) likely contributed to his initial response to treatment, but the tumor’s return is the rule rather than the exception.
The Standard Treatment and Why It Has Barely Changed
Since 2005, the standard approach for newly diagnosed glioblastoma has been a combination of surgery to remove as much tumor as possible, followed by radiation therapy with concurrent and adjuvant temozolomide, a chemotherapy drug taken by mouth.4PubMed. Early onset radiation-induced leukoencephalopathy in patients treated for a glioblastoma by STUPP protocol and risk factors evaluation, an ancillary study of the phase III ASTER protocol This combination, commonly known as the Stupp protocol after the physician who led the clinical trial establishing it, remains the standard of care. The fact that the same regimen has been the go-to approach for two decades speaks less to its effectiveness and more to how difficult it has been to find anything better.5PubMed Central. Optimizing the Stupp protocol for treatment of glioblastoma: eliminating age bias, enhancing treatment timing, use of stereotactically-guided sequential boost, and dexamethasone dosing
Glioblastoma resists treatment partly because its cells invade deeply into surrounding brain tissue, making complete surgical removal virtually impossible. Even when imaging suggests the visible tumor has been removed, microscopic clusters of cancer cells remain embedded in functioning brain. The tumor also tends to be genetically diverse within a single patient, meaning that even if chemotherapy kills 99 percent of the cells, the surviving fraction can have entirely different vulnerabilities and keep growing.
One molecular marker that does make a difference in how well treatment works is MGMT promoter methylation, a chemical modification that essentially silences a gene that helps cancer cells repair the damage caused by temozolomide. Patients whose tumors carry this methylation tend to respond better to the drug and live longer.6PubMed Central. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH -mutant glioblastoma In tumors without this methylation, temozolomide is considerably less effective, and patients with unmethylated MGMT face worse outcomes overall.7Brain Research. Impact of IDH mutation and MGMT methylation as Independent prognostic markers in uniformly treated high grade glioma Patients This is one reason two glioblastoma patients receiving the same treatment can have very different experiences. When public figures die quickly despite aggressive therapy, it often reflects unfavorable tumor biology rather than a failure of effort.
What Families Actually Witness
The public narratives around notable glioblastoma deaths tend to focus on courage, advocacy, and legislative legacies. What rarely gets discussed in detail is the cognitive and personality deterioration that accompanies the disease. Because the tumor grows inside the brain, it disrupts the very traits that make a person recognizable to the people who love them. Caregivers of glioblastoma patients report that memory problems, changes in personality and mood, and language difficulties are the symptoms that affect their daily lives the most.8PubMed Central. Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
This combination is particularly devastating because it is qualitatively different from caring for someone with most other cancers. A patient with advanced lung cancer or pancreatic cancer faces severe physical decline, but typically remains cognitively themselves until close to the end. A glioblastoma patient may lose the ability to speak coherently, to recognize family members, or to regulate emotions, sometimes while still appearing physically healthy. The psychological toll on caregivers is correspondingly high, driven by the combination of neurological decline, behavioral change, and the speed at which patients go from independence to complete dependency.9Asia-Pacific Journal of Oncology Nursing. Caregiver burden, quality of life, and psychosocial outcomes among informal caregivers of patients with glioma
Ted Kennedy’s family spoke publicly about his determination to remain active in the Senate as long as possible, but his final months were spent largely out of public view as cognitive function declined. The Biden family’s accounts of Beau Biden’s final weeks similarly alluded to a rapid deterioration. These are not simply stories of “losing a battle.” They are stories of watching someone’s personality dissolve while their body persists, and that distinction matters for understanding why the disease carries a kind of terror that survival statistics alone do not capture.
The Awareness Gap Between Famous Patients and Everyone Else
The deaths of senators and celebrities put glioblastoma into headlines, but the disease affects roughly 12,000 to 15,000 Americans each year, the vast majority of whom navigate treatment without media coverage, political connections, or financial security. Research into treatment access has found significant disparities tied to insurance status, income, and race. Economic factors play a substantial role in whether patients receive the full standard-of-care treatment, and patients from lower-income households are less likely to get chemotherapy after surgery and radiation.10PubMed Central. Racial and social-economic inequalities in systemic chemotherapy use among adult glioblastoma patients following surgery and radiotherapy
Hispanic patients face compounding barriers. A study using a national database found that older age, treatment at community rather than academic facilities, lack of insurance, lower income, lower education levels, and the presence of other health conditions all significantly reduced the odds of receiving the full combination of surgery, radiation, and chemotherapy.11PubMed. Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States In practical terms, this means that the treatment John McCain received as a matter of course is functionally unavailable to some portion of patients diagnosed with the same disease, simply because of where they live or what insurance they carry.
The awareness campaigns that followed McCain’s and Kennedy’s deaths directed some fundraising toward glioblastoma research, and advocacy groups have used their stories to lobby for increased NIH funding. But the structural barriers to treatment access remain largely intact, and the gap between what is possible at a major academic medical center and what is available at a community hospital continues to shape outcomes in ways that have nothing to do with tumor biology.
Glioblastoma in Children and Younger Adults
When the public thinks of glioblastoma, the image is usually of an older adult. Beau Biden and Brittany Maynard challenged that expectation by being diagnosed in their forties and twenties, respectively, but the disease can also strike children. Pediatric glioblastoma is rare but behaves differently at the molecular level than the adult form. Research has found that pediatric glioblastoma cells show higher levels of DNA and RNA synthesis activity compared to adult glioblastoma cells, pointing to distinct underlying biology rather than simply the same disease appearing at a younger age.12PubMed Central. Spectral discrimination of pediatric SF188 and adult glioblastoma stem cells by deep learning–enhanced Raman profiling
This distinction matters because treatments developed primarily against adult glioblastoma may not address the specific vulnerabilities of pediatric tumors, and vice versa. One known risk factor for glioblastoma in younger patients is prior radiation therapy for another childhood cancer. Studies have shown that radiation-induced gliomas harbor a pattern of genetic alterations that closely resemble a specific subtype of spontaneous pediatric glioblastoma, suggesting that a particular type of brain cell may be especially vulnerable to damage from radiation.13Nature Communications. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B For childhood cancer survivors, this is a sobering footnote: the radiation that saved their life from one cancer can, in rare cases, seed the conditions for a glioblastoma years later.
Dogs, Unlikely Research Allies
One of the more unexpected avenues of glioblastoma research involves pet dogs. Certain breeds, particularly brachycephalic (short-nosed) breeds like boxers, Boston terriers, and bulldogs, develop spontaneous brain tumors that closely resemble human glioblastoma in their biology and behavior. Because these tumors arise naturally in animals with intact immune systems and share many genetic and structural features with the human disease, dogs are increasingly being used as a translational research model.14PubMed Central. A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma
The advantage over laboratory mice, which are the traditional model, is significant. Mouse models typically involve implanting human tumor cells into immunocompromised animals, a setup that cannot fully replicate how the immune system interacts with a growing tumor. In dogs, the tumor develops on its own in a functioning brain with a normal immune response, which makes clinical trials in dogs potentially more predictive of what will work in people.15Glioblastoma – Current Evidence. Canine Glioma as a Model for Human Glioblastoma Veterinary clinical trials testing new immunotherapies and drug delivery methods in dogs with brain tumors are already underway, and findings from these trials are being used to inform the design of human trials. It is a rare case where treating a sick pet and advancing human cancer research serve the same goal simultaneously.